http://www.theedgemarkets.com/article/third-wave-l
Post# of 36537
Last Tuesday, Bintai Kinden Corp Bhd entered into a distribution and licensing agreement with US-based firm Generex Biotechnology Corp and its subsidiary NuGenerex Immuno-Oncology Inc for their Covid-19 vaccine in Malaysia.
This agreement is in relation to the memorandum of understanding and heads of agreement signed with the respective companies in August and September.
Generex is among the 151 candidate vaccines that are in pre-clinical evaluation, according to the WHO document.